S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
NASDAQ:CKPT

Checkpoint Therapeutics (CKPT) Stock Forecast, Price & News

$1.43
+0.04 (+2.88%)
(As of 05/20/2022 06:55 PM ET)
Add
Compare
Today's Range
$1.34
$1.46
50-Day Range
$0.97
$1.89
52-Week Range
$0.96
$4.64
Volume
295,800 shs
Average Volume
1.25 million shs
Market Capitalization
$129.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.71
30 days | 90 days | 365 days | Advanced Chart
Receive CKPT News and Ratings via Email

Sign-up to receive the latest news and ratings for Checkpoint Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Checkpoint Therapeutics logo

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CKPT
Fax
N/A
Employees
14
Year Founded
N/A

Sales & Book Value

Annual Sales
$270 thousand
Book Value
$0.22 per share

Profitability

Net Income
$-56.67 million
Net Margins
-26,592.46%
Pretax Margin
-26,592.46%

Debt

Price-To-Earnings

Miscellaneous

Free Float
85,064,000
Market Cap
$129.54 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/12/2022
Today
5/23/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.77 out of 5 stars

Medical Sector

835th out of 1,416 stocks

Pharmaceutical Preparations Industry

414th out of 677 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -













Checkpoint Therapeutics (NASDAQ:CKPT) Frequently Asked Questions

Is Checkpoint Therapeutics a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Checkpoint Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Checkpoint Therapeutics stock.
View analyst ratings for Checkpoint Therapeutics
or view top-rated stocks.

When is Checkpoint Therapeutics' next earnings date?

Checkpoint Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Checkpoint Therapeutics
.

How were Checkpoint Therapeutics' earnings last quarter?

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) issued its quarterly earnings results on Thursday, May, 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by $0.06. Checkpoint Therapeutics had a negative net margin of 26,592.46% and a negative trailing twelve-month return on equity of 173.15%.
View Checkpoint Therapeutics' earnings history
.

What price target have analysts set for CKPT?

2 brokerages have issued twelve-month price targets for Checkpoint Therapeutics' stock. Their forecasts range from $18.00 to $26.00. On average, they anticipate Checkpoint Therapeutics' stock price to reach $22.50 in the next year. This suggests a possible upside of 1,473.4% from the stock's current price.
View analysts' price targets for Checkpoint Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Checkpoint Therapeutics' key executives?
Checkpoint Therapeutics' management team includes the following people:
What other stocks do shareholders of Checkpoint Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Checkpoint Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), PTC Therapeutics (PTCT), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Aldeyra Therapeutics (ALDX), Kadmon (KDMN) and Rigel Pharmaceuticals (RIGL).

What is Checkpoint Therapeutics' stock symbol?

Checkpoint Therapeutics trades on the NASDAQ under the ticker symbol "CKPT."

Who are Checkpoint Therapeutics' major shareholders?

Checkpoint Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.33%), Healthcare of Ontario Pension Plan Trust Fund (1.22%), Morgan Jess S & Co. Inc. (1.21%), Renaissance Technologies LLC (1.02%), Royal Bank of Canada (0.25%) and State Street Corp (0.23%). Company insiders that own Checkpoint Therapeutics stock include James F Oliviero III and William Garrett Gray.
View institutional ownership trends for Checkpoint Therapeutics
.

Which major investors are selling Checkpoint Therapeutics stock?

CKPT stock was sold by a variety of institutional investors in the last quarter, including Morgan Jess S & Co. Inc.. Company insiders that have sold Checkpoint Therapeutics company stock in the last year include James F Oliviero III, and William Garrett Gray.
View insider buying and selling activity for Checkpoint Therapeutics
or view top insider-selling stocks.

Which major investors are buying Checkpoint Therapeutics stock?

CKPT stock was purchased by a variety of institutional investors in the last quarter, including Healthcare of Ontario Pension Plan Trust Fund, Renaissance Technologies LLC, Goldman Sachs Group Inc., Royal Bank of Canada, Park Avenue Securities LLC, Advisor Group Holdings Inc., Simplex Trading LLC, and Group One Trading L.P..
View insider buying and selling activity for Checkpoint Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Checkpoint Therapeutics?

Shares of CKPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Checkpoint Therapeutics' stock price today?

One share of CKPT stock can currently be purchased for approximately $1.43.

How much money does Checkpoint Therapeutics make?

Checkpoint Therapeutics has a market capitalization of $129.54 million and generates $270 thousand in revenue each year. The company earns $-56.67 million in net income (profit) each year or ($0.85) on an earnings per share basis.

How many employees does Checkpoint Therapeutics have?

Checkpoint Therapeutics employs 14 workers across the globe.

What is Checkpoint Therapeutics' official website?

The official website for Checkpoint Therapeutics is www.checkpointtx.com.

How can I contact Checkpoint Therapeutics?

Checkpoint Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The company can be reached via phone at (781) 652-4500 or via email at [email protected].

This page was last updated on 5/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.